Aliskiren / Hydrochlorothiazide Dosage

This dosage information may not include all the information needed to use Aliskiren / Hydrochlorothiazide safely and effectively. See additional information for Aliskiren / Hydrochlorothiazide.

The information at is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Hypertension

Initial: 150 mg-12.5 mg or 150 mg-25 mg once a day to a maximum of 300 mg-25 mg once a day. Patients should establish a routine pattern for taking aliskiren-hydrochlorothiazide with regard to meals since high-fat meals substantially decrease absorption.

The antihypertensive effect is generally seen within 1 week, with maximal effects seen at around 4 weeks. If blood pressure remains uncontrolled after 2 to 4 weeks of therapy, the dose may be titrated up to a maximum of 300 mg-25 mg.

Renal Dose Adjustments

CrCl less than 30 mL/min: not recommended

Liver Dose Adjustments

No adjustment recommended


Discontinue aliskiren-hydrochlorothiazide in patients with head and neck angioedema and monitor until signs and symptoms resolve.

Correct imbalances of hypotension in volume-depleted or salt-depleted patients before initiating therapy with aliskiren-hydrochlorothiazide.

Aliskiren-hydrochlorothiazide is contraindicated by the manufacturer in patients with severe renal impairment (glomerular filtration rate (GFR) less than 30 mL/min).

Aliskiren-hydrochlorothiazide should be titrated slowly in patients with hepatic impairment.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age)


Data not available

Other Comments

Patients switched from monotherapy to combination therapy will experience greater blood pressure reductions with the use of the combination product regardless of the previous dose of the single agent.

Aliskiren-hydrochlorothiazide may be administered with other antihypertensive agents; however, additive effects with maximal doses of ACE inhibitors and beta blockers have not been demonstrated.